Literature DB >> 11122880

Brain tumor clinical trials: pitfalls and promise for the future.

M R Gilbert1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11122880     DOI： 10.1007/s11912-000-0095-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  22 in total

Review 1.  Complexities, pitfalls, and strategies for evaluating brain tumor therapies.

Authors:  R S Kaplan
Journal:  Curr Opin Oncol       Date:  1998-05       Impact factor: 3.645

2.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

3.  Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy.

Authors:  M D Prados; C Scott; W J Curran; D F Nelson; S Leibel; S Kramer
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

4.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

Authors:  W K Yung; M D Prados; R Yaya-Tur; S S Rosenfeld; M Brada; H S Friedman; R Albright; J Olson; S M Chang; A M O'Neill; A H Friedman; J Bruner; N Yue; M Dugan; S Zaknoen; V A Levin
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

5.  The New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Organization, Objectives, and Activities.

Authors: 
Journal:  Cancer Control       Date:  1998-03       Impact factor: 3.302

Review 6.  The new WHO classification of brain tumours.

Authors:  P Kleihues; P C Burger; B W Scheithauer
Journal:  Brain Pathol       Date:  1993-07       Impact factor: 6.508

7.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

8.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch
Journal:  J Natl Cancer Inst       Date:  1993-05-05       Impact factor: 13.506

9.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

10.  Selection bias, survival, and brachytherapy for glioma.

Authors:  R C Florell; D R Macdonald; W D Irish; M Bernstein; S A Leibel; P H Gutin; J G Cairncross
Journal:  J Neurosurg       Date:  1992-02       Impact factor: 5.115
View more
  1 in total

Review 1.  Prospective clinical trials of brain tumor therapy: the critical role of neurosurgeons.

Authors:  Frederick F Lang; Anthony Asher
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.